Immunisation fund tops $US1b, WHO calls for free anti-TB drugs

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.422, 2003-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics of anti-TB drugs-related hepatotoxicity

By Roy Puspita Das Majumder Mousumi Roy Bidyut

Pharmacogenomics, Vol. 9, Iss. 3, 2008-03 ,pp. : 311-321

Future Medicine

Access to resources Recommend Favorite

High prevalence of resistance to second-line anti-TB drugs

Reactions Weekly, Vol. 1, Iss. 1418, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers

Current Drug Metabolism, Vol. 16, Iss. 7, 2015-09 ,pp. : 538-552

Bentham Science Publishers

Access to resources Recommend Favorite

WHO calls for meningitis funds, drugs to treat CVD

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 389, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Computer-aided Identification of Novel DprE1 Inhibitors as Potential Anti-TB Lead Compounds: A Hybrid Virtual-screening and Molecular Dynamics Approach

Letters in Drug Design & Discovery, Vol. 12, Iss. 4, 2015-05 ,pp. : 302-313

Bentham Science Publishers

Access to resources Recommend Favorite